ARTIRIA Medical, a neurovascular company providing disruptive minimally invasive stroke treatments has raised a CHF 3 million Series A financing round to accelerate its path-to-market through clinical validation and regulatory approval.

The investment round, led by 4FO Venture Partners, was joined by investiere, Zürcher Kantonalbank (ZKB), NEST pension fund, Venture Kick and business angels. investiere contributed CHF 0.8 million.

With this financing round, the company also announces the appointment of three outstanding experts to its board of directors; Jacques Essinger (Founder of Polares, former CEO of Symetis), Jean-Pierre Rosat (General Partner of 4FO Venture) and Didier Cowling (former CEO of Kuros Bioscience) who will help bring this innovation to patients.

ARTIRIA will use the capital to accelerate the clinical and regulatory development of its patented micro-actuated device which has potential to significantly improve stroke treatment. The funds will be invested in R&D, product verification and certification through clinical validation.

How does one operate inside the brain? We asked a neurosurgeon and this is what he told us. 

“Our cutting-edge technology allows micromotion deep in the brain arteries, thus enabling seamless navigation towards a cerebral lesion.” says Guillaume Petit-Pierre, Founder and CEO of ARTIRIA. In this interview, he explains how the idea for the company was born. 

We’ve invested in Artiria because they’ve developed a beautifully simple but cutting-edge medtech device that saves time and costs in hospitals and improves patient outcomes.

New call-to-action